Sign In
Buy SNY
$43.98
-0.680 (-1.52%)
At Close: Jul 20, 2026
Press Release: Sanofi reaches agreement with the US government to lower medicine costs while strengthening innovation
02:21pm, Friday, 19'th Dec 2025
Sanofi reaches agreement with the US government to lower medicine costs while strengthening innovation Agreement delivers on President Trump's four requests, establishing a framework for lower prices
SNY's Rare Disease Drug Efdoralprin Alfa Gets EMA's Orphan Drug Tag
11:56am, Thursday, 18'th Dec 2025
Sanofi gains EMA Orphan Drug status for efdoralprin alfa, a phase II biologic for AATD-related emphysema with promising dosing data.
Sanofi (SAN:CA) Discusses Year-End Late-Stage Pipeline Review With Focus on Clinical and Regulatory Developments Transcript
09:59pm, Tuesday, 16'th Dec 2025
Sanofi (SAN:CA) Discusses Year-End Late-Stage Pipeline Review With Focus on Clinical and Regulatory Developments Transcript
SNY Stock Down on Double Trouble With Multiple Sclerosis Drug
11:46am, Tuesday, 16'th Dec 2025
Sanofi shares slide after the FDA again delays its review of its MS drug tolebrutinib, and a phase III study fails to hit its primary endpoint.
South Korea's ADEL signs up to $1.04 billion Alzheimer's drug development deal with Sanofi
06:57pm, Monday, 15'th Dec 2025
South Korea-based ADEL said late on Monday that it has entered a $1.04 billion partnership with French drugmaker Sanofi to develop and sell the biotech company's experimental Alzheimer's disease treat
Sanofi: Today's Tolebrutinib Setback Shouldn't Worry Shareholders - This Is Why
02:51pm, Monday, 15'th Dec 2025
Sanofi faces a setback as tolebrutinib fails its Phase 3 PPMS trial, halting regulatory pursuit for this indication. Meanwhile, an approval decision on the candidate has also been delayed. SNY's growt
Sanofi Expands Dren Bio Partnership With Potential $1.7 Billion Autoimmune Disease Collaboration
01:10pm, Monday, 15'th Dec 2025
Dren Bio, a privately held, clinical-stage biotechnology company, has a new collaboration with Sanofi SA (NASDAQ: SNY). The new agreement is built on the existing relationship between the two companie
Dren Bio to collaborate with Sanofi to develop autoimmune disease therapies for up to $1.7 billion
08:21am, Monday, 15'th Dec 2025
Dren Bio, a private biotech company, said on Monday it has entered into a strategic collaboration with Sanofi to develop therapies for autoimmune diseases in a deal worth up to $1.7 billion.
Dren Bio Expands Strategic Collaboration with Sanofi to Develop Next-Generation B-Cell Depletion Therapy
08:05am, Monday, 15'th Dec 2025
SAN CARLOS, Calif.--(BUSINESS WIRE)--Dren Bio Expands Strategic Collaboration with Sanofi to Develop Next-Generation B-Cell Depletion Therapy.
Sanofi shares slide as FDA delays MS drug decision and late-stage trial disappoints
05:48am, Monday, 15'th Dec 2025
Shares of French pharmaceutical group Sanofi fell sharply on Monday after the company flagged another delay to a US regulatory decision for its experimental multiple sclerosis drug tolebrutinib and re
Cullen Capital Management LLC Acquires 36,714 Shares of Sanofi $SNY
05:11am, Monday, 15'th Dec 2025
Cullen Capital Management LLC raised its holdings in shares of Sanofi (NASDAQ: SNY) by 9.2% in the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commissio
Sanofi stock slumps after two setbacks on multiple-sclerosis drug
04:43am, Monday, 15'th Dec 2025
Shares of Sanofi slumped on Monday as the French drugmaker said a U.S. regulatory review of its multiple-sclerosis drug won't be completed by the end of the year and that a trial for a different form
Sanofi flags delay in FDA's decision on tolebrutinib, shares fall
03:49am, Monday, 15'th Dec 2025
French pharmaceutical group Sanofi said on Monday the U.S. Food and Drug Administration's decision on its investigative drug to treat multiple sclerosis was expected to be delayed until the first quar
Sanofi Multiple Sclerosis Drug Hit by Double Setback
01:56am, Monday, 15'th Dec 2025
A U.S. regulatory decision on tolebrutinib will again be delayed while a late-stage trial of the drug for a different form of the disease didn't hit its main goal.
Press Release: Sanofi provides update on tolebrutinib in primary progressive multiple sclerosis
01:05am, Monday, 15'th Dec 2025
Sanofi provides update on tolebrutinib in primary progressive multiple sclerosis PERSEUS phase 3 study in primary progressive multiple sclerosis did not meet its primary endpoint in delaying time to
